Literature DB >> 33336780

Possible treatment and strategies for COVID-19: review and assessment.

N Trivedi1, A Verma, D Kumar.   

Abstract

The coronavirus disease 2019 (COVID-19) is declared as an international emergency in 2020. Its prevalence and fatality rate are rapidly increasing but the medication options are still limited for this perilous disease. The emergent outbreak of COVID-19 triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps propagating globally. The present scenario has emphasized the requirement for therapeutic opportunities to relive and overcome this latest pandemic. Despite the fact, the deteriorating developments of COVID-19, there is no drug certified to have considerable effects in the medical treatment for COVID-19 patients. The COVID-19 pandemic requests for the rapid testing of new treatment approaches. Based on the evidence, hydroxychloroquine is the first medicine opted for the treatment of disease. Umifenovir, remdesivir, and fevipiravir are deemed the most hopeful antiviral agent by improving the health of infected patients. The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and it is shown in a randomized clinical trial by the United Kingdom that it reduced the death rate in COVID-19 patients. The current review recapitulates the existing evidence of possible therapeutic drugs, peptides, humanized antibodies, convulsant plasma, and vaccination that has revealed potential in fighting COVID-19 infections. Many randomized and controlled clinical trials are taking place to further validate these agent's safety and effectiveness in curing COVID-19.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33336780     DOI: 10.26355/eurrev_202012_24057

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  16 in total

Review 1.  Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review.

Authors:  Antonio Molina-Carballo; Rafael Palacios-López; Antonio Jerez-Calero; María Carmen Augustín-Morales; Ahmed Agil; Antonio Muñoz-Hoyos; Antonio Muñoz-Gallego
Journal:  Curr Issues Mol Biol       Date:  2021-12-22       Impact factor: 2.976

Review 2.  Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Mohammed Alqarni; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 3.  Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Authors:  Devendra Kumar; Neerja Trivedi
Journal:  Biomed Pharmacother       Date:  2021-04-27       Impact factor: 7.419

4.  A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19.

Authors:  Qiang Tang; Yanwei Liu; Yingfeng Fu; Ziyang Di; Kailiang Xu; Bo Tang; Hui Wu; Maojun Di
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

5.  Factors associated with survival of Iranian patients with COVID-19: comparison of Cox regression and mixture cure model.

Authors:  Mozhgan Seif; Mehdi Sharafi; Haleh Ghaem; Farzaneh Kasraei
Journal:  Trop Dis Travel Med Vaccines       Date:  2022-03-01

6.  Monoclonal Antibodies for the Prevention and Treatment of COVID-19 Disease in Patients With Hematological Malignancies: Two Case Reports and a Literature Review.

Authors:  David Klank; Martin Hoffmann; Bernd Claus; Florian Zinke; Raoul Bergner; Peter Paschka
Journal:  Hemasphere       Date:  2021-10-27

Review 7.  Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Authors:  Jiří Beran; Marián Špajdel; Jiří Slíva
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

Review 8.  A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?

Authors:  Antonio Vitiello; Francesco Ferrara
Journal:  Immunol Res       Date:  2021-11-05       Impact factor: 2.829

9.  Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results.

Authors:  Panagiotis Mallis; Theofanis Chatzistamatiou; Zetta Dimou; Eirini-Faidra Sarri; Eleni Georgiou; Maria Salagianni; Vasiliki Triantafyllia; Evangelos Andreakos; Catherine Stavropoulos-Giokas; Efstathios Michalopoulos
Journal:  World J Biol Chem       Date:  2022-03-27

10.  Perception, Attitude, and Confidence of Physicians About Antimicrobial Resistance and Antimicrobial Prescribing Among COVID-19 Patients: A Cross-Sectional Study From Punjab, Pakistan.

Authors:  Khezar Hayat; Zia Ul Mustafa; Muhammad Nabeel Ikram; Muhammad Ijaz-Ul-Haq; Irum Noor; Muhammad Fawad Rasool; Hafiz Muhammad Ishaq; Anees Ur Rehman; Syed Shahzad Hasan; Yu Fang
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.